SCHEMBL27714887

SCHEMBL27714887

Cc1nc(Cl)c(-c2cccc(CN)c2)c(NC2CCCC2)n1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 9/20 0.40
▸ ALDH1A1 P00352 9/20 0.40
▸ TSHR P16473 9/20 0.40
▸ HSD17B10 Q99714 9/20 0.40
▸ CYP3A4 P08684 8/20 0.40
▸ HPGD P15428 6/20 0.40
▸ MAPK1 P28482 3/20 0.40
▸ ALOX15 P16050 3/20 0.40
▸ TP53 P04637 2/20 0.40
▸ HTR1A P08908 1/20 0.40
▸ DRD2 P14416 1/20 0.40
▸ DRD4 P21917 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ TDP1 Q9NUW8 1/20 0.40
▸ F7 P08709 2/20 0.40
▸ PRSS1 P07477 1/20 0.40
▸ PRSS2 P07478 1/20 0.40
▸ PRSS3 P35030 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27735630 0.89 GABBR2 (0.40) KDM4EALDH1A1TSHRHSD17B10CYP3A4
SCHEMBL3113335 0.86 PDE4A (0.41) KDM4EALDH1A1TSHRHSD17B10CYP3A4
SCHEMBL3110556 0.85 ADORA3 (0.50) KDM4EALDH1A1TSHRHSD17B10CYP3A4
SCHEMBL3123037 0.83 PDE5A (0.48) KDM4EALDH1A1TSHRHSD17B10CYP3A4
SCHEMBL3122459 0.80 TP53 (0.49) KDM4EALDH1A1TSHRHSD17B10CYP3A4
SCHEMBL3110916 0.80 PDE4A (0.42) KDM4EALDH1A1TSHRHSD17B10CYP3A4
SCHEMBL27735613 0.79 GABBR2 (0.56) ADORA3ADORA2AADORA2BADORA1
SCHEMBL3126761 0.78 ADORA3 (0.55) KDM4EALDH1A1TSHRHSD17B10CYP3A4
SCHEMBL3108180 0.78 GABBR2 (0.41) KDM4EALDH1A1TSHRHSD17B10CYP3A4
SCHEMBL3121937 0.78 GABBR2 (0.52) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101193868-A Pyrimidine derivatives for the treatment of GABA B mediated nervous system disorders NOVARTIS AG (CH) 2008-06-04 — — CN disclosed
Send feedback